Clinical evaluation of Tc-99m-diethyl-IDA in hepatobiliary disorders

Area of Science:

• Nuclear Medicine
• Hepatology
• Radiopharmacology

Background:

• N,alpha(2,6-diethylacetanilide)-iminodiacetic acid is a novel Tc-99m-labeled radiopharmaceutical.
• This agent is primarily excreted via the biliary tract, enabling visualization of the biliary tree and gallbladder.

Purpose of the Study:

• To evaluate the efficacy of Tc-99m-diethyl-IDA in scintigraphic studies.
• To assess its diagnostic capabilities in normal subjects and patients with hepatobiliary disturbances.

Main Methods:

• Scintigraphic imaging was performed in 20 healthy individuals and 42 patients with hepatobiliary conditions.
• Tracer uptake, distribution, and excretion patterns were analyzed.

Main Results:

• Normal subjects showed typical liver uptake, intrahepatic bile duct accumulation, and gallbladder visualization.
• Hepatocellular damage resulted in depressed tracer uptake.
• Tc-99m-diethyl-IDA clearly demonstrated acute/subacute gallbladder disorders and asymptomatic cholelithiasis with delayed visualization.
• Intrahepatic bile ducts were distended in incomplete obstruction and not visualized in severe hepatocellular damage or complete biliary obstruction.

Conclusions:

• Tc-99m-diethyl-IDA is a valuable tool for diagnosing hepatobiliary and gallbladder diseases.
• Its excretion profile and uptake patterns provide crucial diagnostic information for various liver and biliary conditions.